Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 225-233

  Iusuf, Dilek ^a   Hendrikx, Jeroen J M A ^a,b   Van Esch, Anita ^a   Van De Steeg, Evita ^a   Wagenaar, Els ^a   Rosing, Hilde ^b   Beijnen, Jos H ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

docetaxel; OATP1A 1B; OATP1B1; OATP1B3; organic anion transporting polypeptides (OATPs)

Indexed keywords

DOCETAXEL; POLYSORBATE 80; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; ANTINEOPLASTIC AGENT; ORGANIC ANION TRANSPORTER; POLYSORBATE; SLCO1A2 PROTEIN, HUMAN; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN; TAXOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG LIVER LEVEL; DRUG UPTAKE; HUMAN; IN VIVO STUDY; INTESTINE ABSORPTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OATP1A2 GENE; OATP1B1 GENE; OATP1B3 GENE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC THERAPY; TRANSGENIC MOUSE; ANIMAL; GENETIC COMPLEMENTATION; MEDICINAL CHEMISTRY; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; GENETIC COMPLEMENTATION TEST; HUMANS; INTESTINAL ABSORPTION; MALE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYSORBATES; TAXOIDS;

EID: 84925285661     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28970     Document Type: Article

References (48)

1. Baker SD, Verweij J, Cusatis GA, et al., Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009; 85: 155-63.
2. Baker SD, Sparreboom A, Verweij J,. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006; 45: 235-52.
3. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al., Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117: 3583-92.
4. Chew SC, Singh O, Chen X, et al., The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 2011; 67: 1471-8.
5. Tran A, Jullien V, Alexandre J, et al., Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570-80.
6. Chew SC, Sandanaraj E, Singh O, et al., Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br J Clin Pharmacol 2012; 73: 606-18.
7. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
8. Iusuf D, van de Steeg E, Schinkel AH,. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012; 33: 100-8.
9. Hagenbuch B, Meier PJ,. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-65.
10. Konig J, Seithel A, Gradhand U, et al., Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-43.
11. Niemi M,. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
12. Klaassen CD, Aleksunes LM,. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010; 62: 1-96.
13. Cutler MJ, Choo EF,. Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments. Curr Drug Metab 2011; 12: 793-807.
14. de Graan AJ, Lancaster CS, Obaidat A, et al., Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012; 18: 4433-40.
15. Smith NF, Acharya MR, Desai N, et al., Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4: 815-18.
16. Yamaguchi H, Kobayashi M, Okada M, et al., Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008; 260: 163-9.
17. Hu S, Mathijssen RH, de Bruijn P, et al., Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 2014; 110: 894-8.
18. Moes JJ, Koolen SL, Huitema AD, et al., Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm 2011; 420: 244-50.
19. van de Steeg E, van Esch A, Wagenaar E, et al., High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 2011; 17: 294-301.
20. van de Steeg E, van Esch A, Wagenaar E, et al., Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 2013; 19: 821-32.
21. van de Steeg E, Stranecky V, Hartmannova H, et al., Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122: 519-28.
22. van de Steeg E, Wagenaar E, van der Kruijssen CM, et al., Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010; 120: 2942-52.
23. Engels FK, Verweij J,. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005; 41: 1117-26.
24. Kuppens IE, van Maanen MJ, Rosing H, et al., Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005; 19: 355-61.
25. Iusuf D, Sparidans RW, van Esch A, et al., Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 2012; 9: 2497-504.
26. Ten Tije AJ, Loos WJ, Verweij J, et al., Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. Clin Pharmacol Ther 2003; 74: 509-10.
27. van Tellingen O, Beijnen JH, Verweij J, et al., Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999; 5: 2918-24.
28. Engel A, Oswald S, Siegmund W, et al., Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm 2012; 9: 2577-81.
29. Iusuf D, van Esch A, Hobbs MJ, et al., Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol Pharmacol 2013; 83: 919-29.
30. Iusuf D, van de Steeg E, Schinkel AH,. Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin Pharmacol Ther 2012; 92: 559-62.
31. Kiyotani K, Mushiroda T, Kubo M, et al., Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008; 99: 967-72.
32. Lewis LD, Miller AA, Owzar K, et al., The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 2013; 23: 29-33.
33. Karlgren M, Vildhede A, Norinder U, et al., Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 2012; 55: 4740-63.
34. Gao B, Hagenbuch B, Kullak-Ublick GA, et al., Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000; 294: 73-9.
35. Glaeser H, Bailey DG, Dresser GK, et al., Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81: 362-70.
36. Lee W, Glaeser H, Smith LH, et al., Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005; 280: 9610-17.
37. Obaidat A, Roth M, Hagenbuch B,. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 2012; 52: 135-51.
38. Sissung TM, Reece KM, Spencer S, et al., Contribution of the OATP1B subfamily to cancer biology and treatment. Clin Pharmacol Ther 2012; 92: 658-60.
39. Svoboda M, Wlcek K, Taferner B, et al., Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 2011; 65: 417-26.
40. Bronger H, Konig J, Kopplow K, et al., ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005; 65: 11419-28.
41. Abe T, Kakyo M, Tokui T, et al., Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-63.
42. Maeda T, Irokawa M, Arakawa H, et al., Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010; 122: 180-5.
43. Pressler H, Sissung TM, Venzon D, et al., Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 2011; 6: e20372.
44. Watanabe T, Kusuhara H, Sugiyama Y,. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 2010; 37: 575-90.
45. Yoon I, Han S, Choi YH, et al., Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats. Xenobiotica 2012; 42: 1110-19.
46. Watanabe T, Kusuhara H, Maeda K, et al., Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652-62.
47. Engels FK, Mathot RA, Verweij J,. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007; 18: 95-103.
48. Hennenfent KL, Govindan R,. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006; 17: 735-49.